Clinical trials: sponsored by Anhui Provincial Hospital
Aplastic Anaemia
Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
To evaluate the safety and efficacy of Single Umbilical Cord blood transplantation (sUCBT) containing low dose ATG based conditioning regimen in the treatment of Aplastic Anemia (AA)
- Trial name
- NCT07885982
- Testing
- Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Anhui Provincial Hospital
Hematologic Disease and Disorders
Reconstruction Kinetics of γδ T Cells After Unrelated Cord Blood Transplantation
The primary objective is to investigate the correlation between specific patterns of γδ T cell reconstitution after umbilical cord blood transplantation and key clinical outcomes.
- Trial name
- NCT07782684
- Testing
- Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Anhui Provincial Hospital
Acute Graft-versus-host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with nonmalignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell…
- Trial name
- NCT06294691
- Testing
- Time of stem cell infusion
- Where
- 6 sites in China
- Volunteers
- 198 people
- Sponsor
- Anhui Provincial Hospital
Refractory Thrombocytopenia
A Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of MegaLT Injection for Treating Refractory Thrombocytopenia Following Radiotherapy, Chemotherapy, or Transplantation.
A study to evaluate the safety, efficacy, and pharmacokinetics of MegaLT in treating refractory thrombocytopenia following radiotherapy, chemotherapy, or transplantation.
- Trial name
- NCT06534255
- Testing
- MegaLT injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Anhui Provincial Hospital
Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)
A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD
A study to evaluate the safety and preliminary efficacy of iMSC in subjects with SR-aGVHD
- Trial name
- NCT06321198
- Testing
- iMSC
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Anhui Provincial Hospital
Acute Graft-versus-host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
To observe the effect of stem cell infusion on the development of acute graft-versus-host disease (aGVHD) in patients with malignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation…
- Trial name
- NCT06294678
- Testing
- Time of stem cell infusion
- Where
- 6 sites in China
- Volunteers
- 198 people
- Sponsor
- Anhui Provincial Hospital
Acute Graft Versus Host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT
To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with malignant hematologic diseases after single-unit unrelated cord blood transplantation (sUCBT).
- Trial name
- NCT07047456
- Testing
- Time of umbilical cord blood infusion
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Anhui Provincial Hospital
MDS, AML
QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)
QH101 is an allogeneic TCR-enhanced Vδ2 T cell therapy product engineered to express BTN protein-specific binding elements on the cell surface.
- Trial name
- NCT07131085
- Testing
- Allogeneic TCR-enhanced γδ T cell(QH101), Fludarabine (FLU), Cyclophosphamide (CTX)
- Volunteers
- 9 people
- Sponsor
- Anhui Provincial Hospital
Leukemia
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
CD7 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma. Approximately 10-30% of cute myeloid leukemia(AML) patients exhibit CD7 expression, particularly in early myeloid progenitor cell-derived…
- Trial name
- NCT07120607
- Testing
- CD7 CAR-γδT cell（QH106）, Fludarabine (FLU), Cyclophosphamide (CTX)
- Volunteers
- 9 people
- Sponsor
- Anhui Provincial Hospital
Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM)
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
This is an open label, single-site, dose-escalation study in up to 18 participants with Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma.
- Trial name
- ECAR01 (NCT06961669)
- Testing
- Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
B Lymphoblastic Leukemia/Lymphoma
The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
This study is designed to explore the safety and efficacy for patients with relapsed and/or refractory B-cell lymphoblastic leukemia.
- Trial name
- NCT06307600
- Testing
- RD06-03 cell injection
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Anhui Provincial Hospital
Platelet Recovery After Umbilical Cord Blood Transplantation
Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease
To evaluate the efficacy and safety of Avatrombopag for platelet recovery after unrelated cord blood transplantation (UCBT) in patients with bone marrow failure disease
- Trial name
- AVA (NCT05823376)
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Anhui Provincial Hospital
High Titers of Anti-HLA Antibody (MFI ≥5000)
The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT
Evaluation of the efficacy and safety of immunoadsorption or plasma exchange combined with rituximab and high-dose IVIG to reduce high titres of anti-HLA antibodies in patients prior to allogeneic haematopoietic stem cell…
- Trial name
- NCT06362967
- Testing
- Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Hospital
Prostate Cancer
Pathological Positivity Rate in Prostate Cancer Patients with PI-RADS 4 and First Negative Biopsy
The purpose of this prospective, single-center, single-arm trial was to evaluate the pathologic type of re-treatment based on a clear PI-RADS score of ≥4 with a first negative prostate biopsy, belonging to the high-risk group of…
- Trial name
- NCT06677775
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Hospital
Unresectable Hepatocellular Carcinoma
"cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma
This study is a single-arm, single-center, non-randomized, open-label study. A total of 37 patients with locally advanced or metastatic HCC who have not received systemic therapy, are not suitable for radical surgical resection…
- Trial name
- NCT06590844
- Testing
- Injectable coenzyme I
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Anhui Provincial Hospital
Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm
Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases
Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic…
- Trial name
- NCT06480630
- Testing
- Basiliximab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Anhui Provincial Hospital
Cytomegalovirus Infection Reactivation
Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation
- Trial name
- NCT06441669
- Testing
- Letermovir
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies
- Trial name
- NCT06277011
- Testing
- Metabolically Armed CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
B-cell Acute Lymphoblastic Leukemia
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT05747157
- Testing
- Metabolically Armed CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Myelodysplastic Syndromes
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS
This study aimed to evaluate the safety and efficacy of unrelated umbilical cord blood microtransplantation in the treatment of above-mentioned MDS patients by observing the factors related to the efficacy and adverse reactions.
- Trial name
- NCT06109064
- Testing
- Unrelated Umbilical Cord Blood, Venetoclax, Decetabine
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Anhui Provincial Hospital